World Wires · story 11011 · unverified · 1 source(s)

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk

Open in the desk

Coverage

• Monte Rosa Therapeutics to Present Results of MRT-8102 GFORCE-1 Phase 1 Study in Subjects with Elevated Cardiovascular Disease Risk GlobeNewswire: public companies · tier D · clear net · 2026-09-30 20:01 UTC

What this site indexes